European Patent Office Upholds Angiotech's Patent For Drug-Coated Stents

Law360, New York (January 24, 2005, 12:00 AM EST) -- The European Patent Office has upheld the validity of Canadian medical device maker Angiotech Pharmaceuticals’ patent on specially coated medical stents, the company said Monday.

The EPO maintained the validity of Angiotech's patent with various claims, including claims to stents coated with paclitaxel and a polymeric carrier.

“This decision reaffirms Angiotech's continued patent protection in Europe,” the company said in a statement.

The patent is one of many in Angiotech's portfolio, including the Boston Scientific Taxus stent program. The stents, coated with paclitaxel and a polymeric...
To view the full article, register now.